Comedian Yang Sang-guk recently shared his grief over losing his father to COVID-19 during a televised appearance, recalling how his father’s body was placed in a plastic bag instead of receiving traditional funeral rites due to pandemic protocols. This personal account highlights the ongoing human toll of the virus, even as global health systems adapt to endemic management. While acute mortality has decreased significantly since 2021, vulnerable populations, particularly the elderly with comorbidities, continue to face elevated risks, underscoring the importance of sustained vaccination efforts and equitable access to antivirals in regions with strained healthcare infrastructure.
The Human Dimension of Pandemic Loss: Beyond Statistics
Yang Sang-guk’s testimony reflects a broader societal trauma experienced during the pandemic’s peak, when infection control measures often disrupted cultural and religious mourning practices. In South Korea, where Confucian traditions emphasize elaborate funeral rites, the use of plastic bags for deceased COVID-19 patients was implemented under strict biosafety guidelines to prevent viral transmission via fomites or aerosols during handling. These protocols, while scientifically grounded in minimizing nosocomial spread, added psychological burdens on families already coping with sudden loss. As of early 2026, South Korea maintains a tiered response system for respiratory viruses, with mask recommendations in healthcare settings during seasonal surges but no nationwide mandates, reflecting a shift toward individualized risk assessment guided by the Korea Disease Control and Prevention Agency (KDCA).
In Plain English: The Clinical Takeaway
- COVID-19 remains a serious threat primarily to older adults and those with underlying conditions like heart disease or diabetes, even if average population risk has lowered.
- Vaccination and early antiviral treatment (such as Paxlovid) significantly reduce the chance of severe illness, hospitalization, or death when administered promptly after symptom onset.
- Public health measures like masking in high-risk settings and improved indoor ventilation continue to play a key role in protecting vulnerable individuals during community outbreaks.
Evolving Epidemiology and Regional Healthcare Impacts
Globally, the Omicron lineage continues to dominate circulating strains, with subvariants like XBB.1.5 and subsequent recombinants demonstrating increased immune evasion but generally reduced pathogenicity compared to ancestral strains. According to the World Health Organization’s weekly epidemiological update, as of March 2026, weekly reported COVID-19 deaths have declined by over 90% from the 2021 peak, yet approximately 15,000 deaths are still reported globally each month, with disproportionate impacts in low- and middle-income countries where vaccine access and antiviral distribution remain inconsistent. In the United States, the FDA has maintained emergency use authorization for updated monovalent mRNA vaccines targeting the XBB.1.5 lineage, while the NHS in England offers seasonal booster doses to individuals aged 65 and over, those in clinical risk groups, and frontline healthcare workers. These policies reflect a strategy of prioritizing protection for those most vulnerable to severe outcomes, aligning with WHO’s SAGE recommendations on lifecycle immunization.
“We’ve moved from crisis management to sustained protection — the focus now is on ensuring that high-risk populations receive timely boosters and early treatment access, especially as hybrid immunity wanes over time.”
— Dr. Maria Van Kerkhove, Technical Lead for COVID-19, World Health Organization
Mechanisms, Mitigation, and the Role of Antivirals
The SARS-CoV-2 virus gains entry into human cells primarily through the binding of its spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in respiratory epithelium, cardiovascular tissue, and the gastrointestinal tract. This interaction facilitates viral fusion and replication, triggering both direct cytopathic effects and dysregulated immune responses that can lead to acute respiratory distress syndrome (ARDS) or multi-organ failure in severe cases. Monoclonal antibody therapies, once pivotal in early treatment, have largely been rendered ineffective against current circulating variants due to mutations in the spike protein’s receptor-binding domain. In contrast, oral antivirals like nirmatrelvir (combined with ritonavir as Paxlovid) inhibit the viral main protease (Mpro), a conserved enzyme essential for cleaving viral polyproteins into functional units. This mechanism remains effective across variants, making early antiviral administration a cornerstone of outpatient management for high-risk individuals.
In the European Union, the EMA has affirmed the conditional marketing authorization for Paxlovid, emphasizing its use within five days of symptom onset in adults with at least one comorbidity that increases the risk of severe disease. Real-world data from the EUPAS registry, published in The Lancet Infectious Diseases, show that among patients aged 65 and older, nirmatrelvir use was associated with a 51% reduction in hospitalization or death (adjusted hazard ratio 0.49; 95% CI, 0.42–0.57) compared to non-use, reinforcing its value in mitigating severe outcomes even in the Omicron era.
Contraindications & When to Consult a Doctor
- Individuals with severe hepatic impairment or those taking certain contraindicated medications (such as strong CYP3A inducers like carbamazepine or St. John’s wort) should not receive nirmatrelvir-ritonavir without specialist review due to risk of toxicity or reduced efficacy.
- Patients experiencing persistent shortness of breath, chest pain, confusion, or oxygen saturation below 94% on room air should seek immediate medical evaluation, as these may indicate progression to severe disease requiring hospitalization.
- Those with a history of severe allergic reactions to vaccine components (e.g., polyethylene glycol in mRNA vaccines) should consult an allergist prior to vaccination; alternative platforms like protein-subunit or inactivated vaccines may be suitable.
| Intervention | Target Population | Key Benefit (Real-World Evidence) | Reference |
|---|---|---|---|
| Updated mRNA Booster (XBB.1.5) | Adults ≥65 years or with comorbidities | 41% reduction in symptomatic infection; 72% reduction in severe disease (CDC VISION Network, 2023-2024) | CDC MMWR |
| Nirmatrelvir-Ritonavir (Paxlovid) | High-risk adults within 5 days of symptom onset | 51% lower risk of hospitalization/death in ≥65-year-olds (EUPAS Registry, Lancet Infect Dis 2024) | The Lancet Infectious Diseases |
| ACE2-Targeted Entry Inhibitors (Investigational) | Immunocompromised individuals with poor vaccine response | Phase II: 60% lower viral load at day 5 vs placebo (NIH ACTIV-2, interim) | NIH Clinical Trials |
Funding, Transparency, and Global Equity
The development of nirmatrelvir was supported by Pfizer’s internal research funding, with preclinical and early clinical studies conducted in collaboration with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). The pivotal EPIC-HR trial (NCT04960202), which led to EUA, was funded by Pfizer and enrolled 2,246 non-hospitalized, high-risk adult patients across multiple countries. Transparency in funding sources remains critical for public trust, particularly as pharmaceutical influence shapes treatment guidelines. Meanwhile, global access to antivirals remains uneven: while high-income countries secured early procurement agreements, many African and Southeast Asian nations faced delays due to cost, supply chain constraints, and limited cold-chain infrastructure. Initiatives like the WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool have sought to expand voluntary licensing, though uptake by originator companies has been inconsistent.
“Equitable access to life-saving therapeutics is not a matter of charity — it is a fundamental component of pandemic preparedness. We must build systems that deliver countermeasures based on need, not purchasing power.”
— Dr. Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
The Path Forward: Sustained Vigilance Without Fear
Yang Sang-guk’s emotional recollection serves as a reminder that behind every statistic is a human story of love, loss, and resilience. While the acute emergency phase of the pandemic has passed, the virus continues to circulate, evolving in ways that demand ongoing surveillance, adaptable public health policies, and equitable access to medical countermeasures. Future preparedness hinges on maintaining genomic surveillance networks, investing in pan-coronavirus vaccine research, and strengthening health systems to respond not only to SARS-CoV-2 but to emerging respiratory threats with pandemic potential. For individuals, the most effective tools remain up-to-date vaccination, early testing when symptomatic, and prompt consultation with healthcare providers about eligibility for antivirals — especially for those in high-risk groups. Public health messaging must balance honesty about ongoing risks with compassion, avoiding both complacency and unnecessary alarm.
